Skip to main content
Caplight Logo









HITS Inc.

HITS Inc.

Private
SeoulHealthcare & Life Scienceshttps://hits.ai/

Last Round

Series A

Extension

Nov 13, 2025

Total Funding Raised

$13.04M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

HITS Inc. is a biotechnology company that provides an AI platform for drug discovery, integrating physics and deep learning to accelerate the identification and design of new drug compounds.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Medical AI, Vertical SaaS

Business Model

B2B

Customer Profile

Subscription SaaS, Services & Consulting, Usage-Based SaaS

AI Layer

Application

Keywords

AI drug discoverydrug discovery platformdrug discovery SaaSAI for pharmagenerative drug designvirtual screeningcomputational drug discoveryin silico drug discoveryADME/T predictionAI biotechlead optimizationhit identificationphysics-informed AIagentic AImulti-omics analysis

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

HITS Inc. Comparables

Compare HITS Inc. with similar companies based on industry and business-model similarity.

HITS Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Iktos
85%
Aigen Sciences
83%
Optibrium
81%

HITS Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionNov 13, 2025
Series AFeb 14, 2022
SeedOct 1, 2020

Key People

Founding team and executive leadership

Woo Youn Kim

Chief Executive Officer

Executive Team

HITS Inc. Investors

Notable investors and investment history

HITS Inc. investors
InvestorRounds
Korea Investment PartnersSeries A Extension, Seed, Series A
Company K PartnersSeries A
SchmidtSeed
Kiwoom InvestmentSeries A Extension, Series A
Capstone Partners KoreaSeries A
STIC VenturesSeries A Extension, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 20, 2026

    Open roles increased to 48, 2.5x the trailing average.

  • May 1, 2026

    Launched HyperLab, an AI drug development SaaS platform.

HITS Inc. Filings

Explore SEC and related filing metadata, where available.

HITS Inc. filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about HITS Inc.'s valuation, stock price, and market status.

Is HITS Inc. a public or private company?

HITS Inc. is a private company.

What is the current stock price of HITS Inc.?

HITS Inc. is a private company with no public stock price. No recent secondary market data is available.

How much is HITS Inc. worth (valuation)?

Valuation information for HITS Inc. is not publicly available.

Can I buy HITS Inc. stock?

HITS Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was HITS Inc.'s last funding round?

HITS Inc.'s most recent funding round was Series A Extension on November 13, 2025.

Who are the main investors in HITS Inc.?

Key investors in HITS Inc. include Korea Investment Partners.

Will HITS Inc. IPO soon?

No public IPO plans have been announced for HITS Inc..

How can I track HITS Inc. secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor HITS Inc.'s secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSeoul
Employee Range29
Year Founded2020
Last FundingNov 13, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?